Idera Pharmaceuticals Announces Corporate Organizational Changes
September 11 2018 - 7:00AM
- Bryant D. Lim appointed as General
Counsel and Secretary of the Board of Directors -
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical
company focused on the development and commercialization of its
proprietary immune modulator, tilsotolimod, for the treatment of
cancer, today announced several organization updates. The
company has appointed Bryant D. Lim as Senior Vice President,
General Counsel and Secretary of the Board of Directors.
Mr. Lim most recently served as Vice President, Assistant
General Counsel of Incyte Corporation. Prior to Incyte, Mr.
Lim held roles of increasing responsibility at ViroPharma
Incorporated, Merck & Co., Inc. and Morgan, Lewis &
Bockius, LLP. Mr. Lim began his legal career as a law clerk
for a federal judge. Mr. Lim received his J.D. from Villanova
University School of Law, where he serves on its adjunct faculty.
Mr. Lim received his Bachelor of Arts from University of
Rochester.
“Bryant’s experiences with Incyte will be incredibly valuable to
us as we advance tilsotolimod. Bryant also played an integral
role in helping to shape the legal landscape at ViroPharma as the
company matured into a commercial entity and I am thrilled to be
working together with him again as Idera advances towards becoming
a commercial organization,” stated Vincent Milano, Idera’s Chief
Executive Officer.
“It is an exciting time in the field of immuno-oncology and
equally exciting time to be joining Idera to take part in the
development of tilsotolimod,” stated Bryant Lim, Idera’s General
Counsel. “I’m also looking forward to working together again
with Vin and the team as we drive Idera towards commercialization
of tilsotolimod.”
The company also announced the planned departure of Chief
Financial Officer, Louis J. Arcudi III as a result of the company’s
recently announced consolidation to Exton, PA headquarters.
Mr. Arcudi joined Idera in 2007 and during his tenure, played an
instrumental role in continuing to move Idera forward including
several business development deals as well as capital financings
and Idera’s initial listing on the NASDAQ market. The company
expects that Mr. Arcudi will continue to serve as Chief Financial
Officer through October 31, 2018 and that Mr. Arcudi will serve as
an advisor to the company through a consulting agreement after that
time.
Continued Milano, “Although it is personally disappointing to me
that Lou will no longer be with us on a day-to-day basis as a
result of our decision to consolidate all of our operations in
Pennsylvania; I am incredibly grateful for all he has done during
his tenure to continue to move Idera forward, often during
challenging circumstances and often well beyond the typical
functions of a Chief Financial Officer.”
“I will sincerely miss my Idera family of the past 11 years,”
stated Louis J. Arcudi, III. “I am a very strong believer in
tilsotolimod and the team developing this drug and I look forward
to seeing the positive impact that it will have on the lives of
patients both in melanoma and beyond.”
Mr. John Kirby, Idera’s Vice President of Finance and previously
its Vice President of Accounting, will assume leadership of Idera’s
Finance function upon Mr. Arcudi’s departure. Mr. Kirby has
been with Idera since 2015 and previously held positions of
increasing responsibility at Endo Pharmaceuticals, ViroPharma
Incorporated, Astra Zeneca, and KPMG.
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and Idera’s
experience in developing proprietary immunology technologies,
Idera’s lead development program is focused on priming the immune
system to play a more powerful role in fighting cancer, ultimately
increasing the number of people who can benefit from immunotherapy.
Idera is committed to working with investigators and partners who
share the common goal of addressing the unmet needs of patients
suffering from difficult to treat, unmet cancers. To learn more
about Idera, visit www.iderapharma.com.
Forward Looking Statements This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. All statements,
other than statements of historical fact, included or incorporated
in this press release are forward-looking statements. The words
“believes,” “anticipates,” “estimates,” “plans,” “expects,”
“intends,” “may,” “could,” “should,” “potential,” “likely,”
“projects,” “continue,” “will,” and “would” and similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.
Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements and you should not place undue reliance on the Company’s
forward-looking statements. There are a number of important factors
that could cause Idera’s actual results to differ materially from
those indicated or implied by its forward-looking statements,
including those important factors set forth under the caption “Risk
Factors” in the Company’s Annual Report on Form 10-K for the period
ended December 31, 2017. Although Idera may elect to do so at some
point in the future, the Company does not assume any obligation to
update any forward-looking statements and it disclaims any
intention or obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Investor and Media ContactRobert DoodyVice
President, Investor Relations and Corporate CommunicationsOffice:
484-348-1677rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2024 to Jun 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Jun 2023 to Jun 2024